Effectiveness of treatment moderate ulcerative colitis with prolonged-release ethylcellulose-coated mesalazine in real clinical practice in Moscow
https://doi.org/10.47619/2713-2617.zm.2021.v2i2;65-74
Abstract
Background and purpose. The aim of this work is to evaluate the efficacy of treatment patients with moderate left-sided and total ulcerative colitis (UC) with prolonged-release ethylcellulose-coated mesalazine. Materials and methods. The clinical analyses of results of treatment UC patients with prolonged-release ethylcellulose-coated mesalazine was performed. Eighty-seven patients with UC, treated with ethylcellulosecoated microgranules of mesalazine, were examined: 38 (43,7 %) men and 49 (56,3 %) women. The age of patients was from 26 to 49 years, median age 38,3±12,6 year. Results. After 2 weeks prolonged-release ethylcellulosecoated mesalazine treatment the response to therapy was demonstrated in majority of UC patients -71 (81,6%). After 12 weeks treatment prolonged remission persisted in 71 (81,6 %) UC patients. Mayo score decreased from 7,6±0,99 to 2,6±0,25 points. Significant decrease of inflammation markers (CRP, ESR, leukocytosis, fecal calprotectin etc) was determined. After 26 weeks of treatment Mayo score was 2,2-2,3 points. Thirty-two (36,8 %) UC patients showed healing of colon mucosa. After 1 year of prolonged-release ethylcellulose-coated mesalazine treatment clinical remission was determined in 69 (79,3%) UC patients with response to therapy, clinical-endoscopic remission- in 32 (36,8 %) patients. During 1 year follow-up no cases of surgical procedure and readmission because of UC reccurence were noted. Conclusion. Treatment of moderate active UC should be started with oral mesalazine ≥3 gr per day and rectal mesalazine. The most appropriate effective and highcompliance forms of mesalazine are prolonged-release forms of meselazine.
About the Authors
O. V. Knyazev
Moscow Clinical Scientific Center named after A. S. Loginov
Research Institute for Healthcare Organization and Medical Management of Moscow Healthcare Department
National Medical Research Center of Coloproctology named after A. N. Ryzhikh
Russian Federation
Russian Federation
MD, Рrofessor, Head of the Department of Treatment of Inflammatory Bowel
Specialist of the Department of Coloproctology
Professor of the Scientific and Еducational department
86, Shosse Entuziastov, 111123, Moscow, Russian Federation
9, Sharikopodshipnikovskaya str., 115088, Moscow, Russian Federation
2, Salyama Adilya str., 123423, Moscow, Russian Federation
A. V. Kagramanova
Moscow Clinical Scientific Center named after A. S. Loginov
Russian Federation
Russian Federation
Candidat of Medical Sci., Senior Research Associate
86, Shosse Entuziastov, 111123, Moscow, Russian Federation
A. V. Veselov
Research Institute for Healthcare Organization and Medical Management of Moscow Healthcare Department
Russian Federation
Russian Federation
senior specialist of the Organizational and Methodological Department of Coloproctology
9, Sharikopodshipnikovskaya str., 115088, Moscow, Russian Federation
T. V. Skurko
Research Institute for Healthcare Organization and Medical Management of Moscow Healthcare Department
National Medical Research Center of Coloproctology named after A. N. Ryzhikh
Russian Federation
Russian Federation
Candidat of Medical Sci., Head of the Organizational and Methodological Department of Coloproctology
9, Sharikopodshipnikovskaya str., 115088, Moscow, Russian Federation
2, Salyama Adilya str., 123423, Moscow, Russian Federation
Review
For citations:
Knyazev O.V., Kagramanova A.V., Veselov A.V., Skurko T.V. Effectiveness of treatment moderate ulcerative colitis with prolonged-release ethylcellulose-coated mesalazine in real clinical practice in Moscow. City Healthcare. 2021;2(2):65-74. (In Russ.) https://doi.org/10.47619/2713-2617.zm.2021.v2i2;65-74
Views:
1
Email this article 